Morgan Lewis has advised a consortium of investors led by the Russia-China Investment Fund on the establishment and development of the Binnopharm Group pharmaceutical holding.
According to Morgan Lewis, “as a result, the holding, which also includes Sistema PJFSC, a publicly-traded Russian investment company, and VTB Group … will become one of the three largest pharmaceutical manufacturers in Russia as part of a long-term strategy to consolidate Russian pharmaceutical market and create a leading producer of medicines and innovative pharmaceuticals.”
RDIF, Sistema PJSFC, and the VTB Group contributed 85.6% of their stake in JSC Alium and Sistema and VTB contributed 56.2% of their stake in OJSC Sintez to Binnopharm Group's equity. Consequentially, Sistema and VTB will hold 79%, the consortium 15.8%, and minority stakeholders 5.2% of the stake in the Binnopharm Group.
The Moscow team of Morgan Lewis included Partner Artem Tamaev and Associates Emil Shagiakhmetov, Valentina Semenikhina, Philip Korotin, Anastasia Kiseleva, and Andrey Ignatenko.
